Ophthalmologists are beginning to identify common adverse side effects seen in patients with cancer receiving immunotherapy. The IASLC Lung Cancer News spoke with Asim V. Farooq, MD, about how best to care for patients experiencing or susceptible to such toxicities. Dr. Farooq is associate professor of Ophthalmology and Vis... Read more
By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) […] Read more
Watch Recording IASLC faculty members from Europe, Asia and North America will discuss systemic therapies including chemotherapy, immunotherapy, and targeted therapy for advanced-stage lung cancer during the COVID-19 global pandemic. […] Read more
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more
By Enza Esposito Nguyen, DNP, RN, ANP-BC Posted: February 12, 2020 Dr. Enza Esposito Nguyen Although we continue to see many immunotherapy clinical trials mature and deliver marvelous improvements […] Read more
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status. […] Read more
By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated […] Read more
Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. […] Read more